Pubblicazioni

SARS-CoV-2 in Myelodysplastic Syndromes: A
Snapshot From Early Italian Experience

HemaSphere

2020

Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score‐matched analysis

Cancer Medicine

2019

Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study

Messa E, Biale L, Castiglione A, Lunghi M, Bonferroni M, Salvi F, Allione B, Ferrero D, Calabrese C, De Gobbi M, Nicoli P, Gioia D, Levis A, Saglio G, Cilloni D.

Leukemia Lymphoma

2017

Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study

Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A.

Br J Hematol

2017

ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems

Buckstein R, Balleari E, Wells R, Santini V, Sanna A, Salvetti C, Crisà E, Allione B, Danise P, Finelli C, Clavio M, Poloni A, Salvi F, Cilloni D, Oliva EN,Musto P, Houston B, Zhu N, Geddes M, Leitch H, Leber B, Sabloff M, Nevill TJ, YeeKW, Storring JM, Francis J, Maurillo L, Latagliata R, Spiriti MAA, Andriani A,Piccioni AL, Fianchi L, Fenu S, Gumenyuk S, Buccisano F.

AM J Hematol

2017

A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia

Valeria Santini, Bernardino Allione, Gina Zini, Daniela Gioia, Monia Lunghi, Antonella Poloni, Daniela Cilloni, Alessandro Sanna, Elisa Masiera, Manuela Ceccarelli, Omar Abdel-Wahab, Adelmo Terenzi, Emanuele Angelucci, Carlo Finelli, Francesco Onida, Anna Maria Pelizzari, Dario Ferrero, Giuseppe SAGLIO, Maria Figueroa, and Alessandro Levis

Leukemia Research

2017

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P

J Clin Oncol

03/2017

Haploidentical bone marrow transplantation in patients with advanced myelodysplastic syndrome.

Riccardo V, Anna Maria R, Carmen DG, Sara A, Germana B, Stefania B, Fabio C, Alida D, Anna G, Livia G, Francesca G, Adalberto I, Teresa L, Carlo M, Maria Teresa VL, Santini V, Andrea B, Emanuele A.

Am J Hematol

03/2017

Treatment of low-risk myelodysplastic syndromes

Santini V.

Hematology Am Soc Hematol Educ Program

12/2016

Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis

Andrieu V, Sanna A, Caille A, Schemenau J, Sudaka I, Siguret V, Malet M, Park S, Bordessoule D, Mairesse J, Gelsi-Boyer V, Cheze S, Beyne-Rauzy O, Sébert M, Sapena R, Zerazhi H, Legros L, Guerci-Bresler A, Amé SN, Germing U, Santini V, Salvi F, Gioia D, Lunghi M, Dreyfus F, Fenaux P; Groupe Francophone des Myélodysplasies, Fondazione Italiana per le Sindromi Mielodisplastiche (FISMonlus), and Düsseldorf MDS Registry.

Br J Haematol

12/2016

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

Kosmider O, Passet M, Santini V, Platzbecker U, Andrieu V, Zini G, Beyne-Rauzy O, Guerci A, Masala E, Balleari E, Bulycheva E, Dreyfus F, Fenaux P, Fontenay M, Park S; GFM, FISM AND D-MDS.

Haematologica

07/2016

Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.

Meldi K, Qin T, Buchi F, Droin N, Sotzen J, Micol JB, Selimoglu-Buet D, Masala E, Allione B, Gioia D, Poloni A, Lunghi M, Solary E, Abdel-Wahab O, Santini V, Figueroa ME

J Clin Invest

05/2015

A Real Life Survey on Erythropoietin Alpha Treatment in a Cohort of 1049 Low Risk MDS Patients: an Italian MDS Registry Study.

E.Messa, D.Gioia, E.Masiera, B.Allione, E. Angelucci, E. Balleari, M. Bonferroni, G. Cametti, R. Centurioni, E.Crisà, D. Cilloni, P.Danise, L. Del Corso, D. Ferrero, C. Finelli, R. Freilone, G. Gaidano, M. Lunghi, P.Musto, E. Oliva, S. Pappano, A. Pelizzari, A. Poloni, V.Santini, F. Salvi, R. Tassara, G. Visani, G. Saglio and A. Levis on behalf the Fondazione Italiana Sindromi Mielodisplastiche (FISM).

MDS Symposium and ASH 2013 oral

12/2013

A DNA Methylation signature at diagnosis distinguishes CMML patients who respond to decitabine.

M. Figueroa, J. Sotzen, O. Abdel-Wahab, A. Levis, E. Masala, V. Santini

Leukemia Research

05/2013

Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

Santini V., Schemenau J., Levis A., Balleari E., Sapena R., Ades L., Guerci A., Beyne-Rauzy O., Gourin MP., Cheze S., Stamatoullas A., Sanna A., Gioia D., Cametti G., Ferrero D., Raffoux E., Rose C., Poloni A., Prebet T., Legros L., Natarajan-Amè S., Fenaux P., Germin U., Dreyfus F., Park S.

Blood

09/2013

Erythropoietin alpha therapy in lower-risk MDS patients: A real life survey from the network of regional italian MDS registries

E. Messa, D. Gioia, B. Allione, E. Balleari, M. Bonferroni, G. Cametti, E. Crisà, D. Cilloni, P.Danise, L. Del Corso, D. Ferrero, R. Freilone, G. Gaidano, M. Lunghi, P. Musto, S. Pappano, A. Pellizzari, A. Poloni, V. Santini, F. Salvi, R. Tassara, G. Saglio A. Levis.

Leukemia Research

05/2013

High Predictive Value of the Revised International Prognostic Scoring Scoring System (IPSS-R): An External Analysis of 646 Patients From a Multiregional Italian MDS Registry

Emanuela Messa,MD, Daniela Gioia, PhD, Andrea Evangelista, Bernardino Allione, MD, Emanuele Angelucci, MD, Enrico Balleari, MD, Marco Calabrese, Massimo Catarini, MD, Riccardo Centurioni, MD, Paolo Danise, MD, Liset Del Corso, Elisa Masiera, Pellegrino Musto, Fabrizio Pane, Antonella Poloni, MD, Alessandro Sanna, MD, Rodolfo Tassara, MD, Gianni Ciccone, MD, Alessandro Levis, MD, Giuseppe Saglio, MD, Valeria Santini, MD

ASH annual meeting

2012

Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf of the GFM and FISM)

Sophie Park1, Gina Zini, Hematology Professor2,3, Valérie Andrieu4, Alessandro Levis, MD5, Daniela Gioia, PhD6, Eliane Duchayne, MD, PhD, BSc7, Antonella Poloni, MD8, Enrico Balleari, MD9*, Marco Calabrese6*, Isabelle Sudaka10*, Virginie Siguret11*, Martine Guesnu12*, Olivier Kosmider, MD, PhD13*, Michaela Fontenay, MD, PhD14, Alessandro Sanna, MD15, Pierre Lemaire16, Odile Beyne-Rauzy17, Lionel Ades, MD, PhD18, Laurence Legros, MD, PhD19, Paolo Danise, MD20, Pellegrino Musto21, Pierre Fenaux, MD, PhD22, Francois Dreyfus23* and Valeria Santini, MD15

Poster ASH

2012

Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C

Corsetti MT, Salvi F, Perticone S, Baraldi A, De Paoli L, Gatto S, Pietrasanta D, Pini M, Primon V, Zallio F, Tonso A, Alvaro MG, Ciravegna G, Levis A

Leukemia Research

07/2011

Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes

Falco P, Levis A, Stacchini A, Ciriello MM, Geuna M, Notari P, Omedè P, Pautasso M, Prato G, Strola G, Gioia D, Bonferroni M, Cametti G, Ferrero D, Freilone R, Gaidano G, Marinone C, Marmont F, Pollio B, Salvi F, Saglio G, Girotto M

Eur J Haematol

11/2011

Phase II multicenter study of association of arsenic trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndrome

F. Salvi, D. Gioia, MT. Corsetti, AM. Pelizzari, E. Messa, D. Cilloni, G. Cametti, M. Albanesi, A. Colaemma, F. Marmont, E. Audisio, E. Di Bona, M. Lunghi, G. Ciravegna, M. Bonferroni, A. Barbato, B. Baconnet, D. Ferrero, G. Gaidano, A. Gallamini, AM. Liberati, E. Pogliani, G. Rossi, G. Saglio and A. Levis

ASH annual meeting

2009

Presentazione Clinica Delle Sindromi Mielodisplastiche (Mds). Esperienza Del Registro Piemontese Delle Mielodisplasie

Salvi F., Gioia D., Cilloni D., Ferrero D., Marmont F., Audisio E., Boccomini C., Bonferroni M., Cametti G., Ciravegna G., Darbesio A., Dellacasa C., Freilone R., Gatto S.

41° Congresso Nazionale SIE (Società Italiana di Ematologia)

10/2007

Clinical and epidemiological considerations on myelodysplastic syndromes (MDS). The experience of the Piedmont MDS Register

D. Gioia, D. Cilloni, F. Salvi, E. Audisio, C. Boccomini, M. Bonferroni, G. Cametti, G. Ciravegna, A. Darbesio, C. Dellacasa, D. Ferrero, R. Freilone, S. Gatto, M. Lunghi, A. Gallamini, G. Gaidano, M. Girotto, F. Marmont, C. Marinone, E. Messa, S. Perticone, B. Pollio, A.Tonso, G. Saglio, A. Levis

Leukemia Research

Haematologica

05/2007

10/2007

Prognostic Role Of Transfusion Requirement In Myelodisplastic Syndromes

F.Salvi, D.Gioia, D.Cilloni, E.Audisio, C.Boccomini, M.Bonferroni, G.Cametti, G.Ciravegna, A.Darbesio, C.Dellacasa, D.Ferrero, R.Freilone, M.Lunghi, A.Gallamini, G.Gaidano, M.Girotto, F.Marmont, A.Tonso, G.Saglio and A.Levis

9th International Symposium On Myelodysplastic Syndromes

05/2007

Prognostic Role Of Transfusion Requirement In Myelodisplastic Syndromes

F. Salvi, D. Gioia, D. Cilloni, E. Audisio, C. Boccomini, M. Bonferroni, G. Cametti, G. Ciravegna, A. Darbesio, C. Della Casa, D. Ferreo, R. Freilone, M. Lunghi, A. Gallamini, G. Gaidano, M. Girotto, F. Marmont, A. Tonso, G. Saglio, A. Levis

Leukemia Research

05/2007

Response to erythropoietin (EPO) with or without differentiating treatment with 13-cis-retinoic-acid and dihydroxylated vitamin D3 in myelodisplastic syndromes (MDS)

D. Ferrero, D. Gioia, D. Cilloni, E. Audisio, G. Cametti, A. Darbesio, C. Della Casa, M. Lunghi, G. Gaidano, M. Girotto, F. Marmont, E. Messa, S. Perticone, B. Pollio, F. Salvi, A. Tonso, G. Saglio, A. Levis

Leukemia Research

05/2007

Response to erythropoietin (epo) with or without differentiating treatment with 13-cis-retinoic-acid and dihydroxylated vitamin d3 in myelodysplastic syndromes (mds)

D.Ferrero, D.Gioia, D.Cilloni, E.Audisio, G.Cametti, A.Darbesio, C.Dellacasa, M.Lunghi, G.Gaidano, M.Girotto, F.Marmont, E.Messa, B.Pollio, F.Salvi, G.Saglio and A.Levis

9th International Symposium on Myelodysplastic Syndromes

05/2007

Hematology, Piedmont MDS Registry, Italy. Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes

B Pollio, M M Ciriello, A Fruttero, M Geuna, A Iavarone, P Omede’, M Pautasso, A M Pollono, A Santagostino, G Garbaccio Ioria, A Stacchini, D Gioia, D Ferrero, F Marmont, A Gallamini, G Saglio, A Levis and M Girotto

ASH Annual Meeting

2006

Prognostic evaluation of myelodysplastic syndromes (mds): analysis of deaths due to age-related causes

F. Salvi, D.Gioia, S.Gatto, M.Bonferroni, G.Cametti, E.Campa, C.Ceretto, D.Cilloni, A.Darbesio, S.D’Ardia, C.M.Dellacasa, D.Ferrero, F.Ficara, S.Franceschetti, R.Freilone, F.Marmont, E. Scassa, A.Tonso, M.Boccadoro, G.Gaidano, A.Gallamini, E.Gallo, M.Girotto, C.Marinone, G.Saglio, A.Levis

ASH Annual Meeting

2005

Low dose Gemtuzumab Ozogamicin maintenance may prolong remission duration in elderly patients with Acute Myeloid Leukemia and high risk myelodysplasia

F. Marmont, F. Salvi, C. Ceretto, A. Ciocca Vasino, A. Tonso, A. Levis, E. Gallo

Haematologica

07/2005

Analysis of causes of death in Myelodysplastic Syndrome: result emerging from the experience of the Piemonte MDS register

F. Salvi, R. Soave, B. Allione, M. Bonferroni, G. Cametti, C. Ceretto, D. Cilloni, A. Darbesio, S. D’Ardia, C. Dellacasa, D. Ferrero, F. Ficara, S. Franceschetti, R. Freilone, F. Marmont, M. Pini, E. Scassa, A. Tonso, M. Boccadoro, G. Gaidano, A.Gallamini, E. Gallo, G. Saglio, A. Levis

Haematologica

07/2005

Analysis of EVI-1 gene exspression by quantitative real time PCR in Myelodysplastic Syndromes

S. Carturan, E. Gottardi, M. Fava, F. Messa, C. Marinone, F. Salvi, D. Ferrero, I. Defilippi, F. Arruga, E. Gallo, A. Levis, G. Saglio, D. Cilloni

Haematologica

07/2005

Bone marrow blast evaluation in Myelodysplastic Syndrome: problems emerging from the experience of the Piemonte MDS register

F. Salvi, L. Godio, M. Girotto, D. Gioia, B. Allione, A. Baraldi, G. Cametti, C. Cerreto, E. Campa, D. Cilloni, M. Ciriello., C. Dellacasa, D. Ferrero, S. Franceschetti, R. Freilone, F. Marmont, A. Stacchini, S. Tavera, M. Boccadoro, G. Gaidano, E. Gallo, C. Marinone, G. Saglio, A. Levis

Haematologica

07/2005

Dysplasia degree relevance and reproducibility in low-risk Myelodysplastic Syndromes: study from Piedemont MDS registry

M. Bonferroni, D. Ferrero, C. Paparo, F. Salvi, M. Girotto, S. Tavera, M. Grasso, A. Levis, A. Gallamini

Haematologica

07/2005

Prolongation of remission duration with low dose Gemtuzumab Ozogamicin maintenance in a series of elderly patients with Acute Myeloid Leukemia and high risk Myelodysplasia

F. Marmont, C. Ceretto, A. Ciocca Vasino, F. Salvi, L. Depaoli, A. Levis, E. Gallo

Haematologica

06/2005

Different modalities of bone marrow blast quantification can influence diagnostic and prognostic evaluation of Myelodyplastic Syndromes (MDS)

F. Salvi, L. Godio, E. Campa, M.M. Ciriello, D. Ferrero, A. Gallamini, F. Marmont, C. Paparo, A. Stacchini, G. Saglio, A. Levis

Leukemia Research

05/2005

Incorporation of B2M into risk assessment of patients with MDS improves the discriminatory power of the IPSS: validation in an independent population of patients

S. Gatto, G. Mengozzi, S. D’Ardia, G. Cametti, F. Ficara, R. Soave, D. Gioia, A. Baraldi, M. Pini, F. Salvi, A. Levis

Leukemia Research

05/2005

On Behalf Of Piedmont Mds Registry, Italy – Epidemiological Survey On Myelodysplastic Syndromes (Mds) In Piedmont, Italy: Preliminary Evaluation Of Trasfusional Requirements Based On Piedmont Mds Registry Website

F. Salvi, S. Gatto, L. Biale, A. Darbesio, S. Franceschetti, R. Freilone, E. Gallo, M. Girotto, C. Marinone, E. Scassa, G. Saglio

Leukemia Research

05/2005

Definition of RAEB- I and RAEB-II according to the WHO classification of myelodysplastic syndromes (MDS): problems emerging from a large multicenter registry

A. Levis, L. Godio, M. Girotto, M. Bonferroni, T. Callegari, G. Cametti, G. Ciravegna, A. Darbesio, D. Ferrero, F. Ficara, R. Freilone, S. Gatto, F. Marmont, F. Salvi, P. Scaravaglio, A. Stacchini, S. Dardia, A. Tonso, M. Boccadoro, A. Gallamini, E. Gallo, C. Marinone, G. Saglio

ASH Annual Meeting

12/2004

Attenuated flaig regimen in elderly patients with high risk acute myeloid leukemia or myelodysplasia

C. Ceretto, F. Marmont, E. Audisio, M.A. Ciocca Vasino, A. Busca, M. Falda, F. Locatelli, F. Salvi, A. Levis, A. Tonso, E. Gallo

The Hematology Journal 5

06/2004

Correlation between WT1 expression level and the IPSS score in patients affected by myelodysplastic syndromes

D. Cilloni, F. Massa, E. Gottardi, M. Fava, P. Scaravaglio, M. Girotto, C. Marinane, D. Ferrero, A. Gallamini, A. Levis, G. Saglio

ASH Annual Meeting

12/2002

Outcome of elderly patients with acute myeloid leukemia or high risk myelodysplasia treated with an attenuated FLAIG regimen

Marmont F., Audisio E., Ceretto C., Ciocca Vasino A., D’Ardia S., Deapaoli L., Falda M., Levis A., Locatelli F., Tonso A., Gallo E.

Haematologica

10/2003

Piemonte myelodysplastic syndromes (MDS) register: epidemiological considerations

Salvi F., Gatto S., Audisio E., Bonferroni M., Callegari T., Cametti G., Ciravegna G., Ferrero D., Ficara F., Freilone R., Girotto M., Marmont F., Salvio M., Stacchini A, Tonso A., Boccadoro M., Gallamini A., Gallo E., Marinone C., Scassa E. Saglio G., Levis A

Congresso SIE (Società Italiana di Ematologia)

10/2003

Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes

Cilloni D, Gottardi E, Messa F, Fava M, Scaravaglio P, Bertini M, Girotto M, Marinone C, Ferrero D, Gallamini A, Levis A, Saglio G

J Clin Oncol

05/2003

Analysis of FLT-3 ITD and D835 mutation in myelodysplastic syndromes and in chronic myelomonocytic leukemias

A. Serra, E. Gottardi, D. Cilloni, M. Bertini, D. Ferrero, M. Girotto, C. Marinone, A. Levis, G. Saglio

Abstract EHA (European Hematology Association)

06/2002

Clinical heterogeneity and prevalence of normal kariotype myelodysplastic syndromes

P. Scaravaglio, E. Giugliano, D. Cilloni, G. Rege-Cambrin, M. De Petrini, M. Girotto, A. Levis, G. Saglio

Abstract EHA (European Hematology Association)

06/2002